What were Amgen's main revenue drivers in 2004?

Amgen's primary revenue drivers in 2004 were its key therapeutic products, particularly Aranesp®, ENBREL®, and Neulasta®. These products saw significant sales growth due to market share gains and overall market expansion in their respective therapeutic areas.

How did the acquisition of Tularik impact Amgen's financials?

Amgen acquired Tularik Inc. for approximately $1.5 billion in August 2004. This acquisition, accounted for as a business combination, resulted in a charge of $554 million for the write-off of acquired in-process research and development (IPR&D) and contributed to the increase in goodwill. The acquisition aimed to enhance Amgen's drug discovery capabilities in cell signaling and gene expression.

What are the potential impacts of the Medicare Modernization Act (MMA) on Amgen's business?

Amgen anticipates that reimbursement changes resulting from the MMA, particularly the shift to an Average Sales Price (ASP) plus 6% system for certain drugs starting in 2005, are likely to negatively affect product sales for some of its marketed products, including Aranesp®, Neulasta®, and NEUPOGEN®. The company is closely monitoring these changes and their impact on prescription and administration by healthcare providers.

How is Amgen managing its significant investment in research and development?

Amgen continued its strong commitment to R&D in 2004, with R&D expenses increasing to $2.03 billion. The company focuses its R&D efforts on novel therapeutics across oncology, inflammation, metabolic disorders, neuroscience, and general medicine, employing a modality-independent approach. Investments are also driven by acquisitions and licensing agreements to strengthen its product pipeline and discovery capabilities.

AMGN 10-K FY2004 Annual Report — Revenue, Net Income, EPS

Summary

Amgen Inc. reported strong performance in its 2004 annual filing, showcasing significant revenue growth driven by its key therapeutic products. The company's strategic focus on nephrology, supportive cancer care, and inflammatory diseases, supported by blockbuster drugs like EPOGEN®, Aranesp®, Neulasta®, NEUPOGEN®, and ENBREL®, continued to yield substantial sales. The filing highlighted key product developments, including expanded indications and new formulations for ENBREL® and Aranesp®, alongside the introduction of Sensipar® and Kepivancetm. Financially, Amgen demonstrated robust revenue growth, with total revenues reaching $10.55 billion and net income at $2.36 billion for the year. The company also made significant investments in research and development, evidenced by increased R&D expenses and the strategic acquisition of Tularik Inc. for approximately $1.5 billion. However, the company also faced evolving regulatory landscapes, particularly with the Medicare Modernization Act (MMA) potentially impacting future reimbursement rates, and ongoing legal proceedings related to patent and pricing practices, which Amgen believes will not materially affect its financial statements. The company also highlighted its strong liquidity position with substantial cash reserves.

Key Highlights

1Total revenues reached $10.55 billion in 2004, a significant increase from $8.36 billion in 2003, driven by strong product sales.
2Net income for 2004 was $2.36 billion, or $1.81 per diluted share, showing continued profitability.
3Key products like Aranesp®, ENBREL®, and Neulasta® were primary drivers of sales growth.
4Amgen acquired Tularik Inc. for approximately $1.5 billion in August 2004 to enhance its drug discovery capabilities.
5Significant R&D investment continued, with R&D expenses increasing to $2.03 billion in 2004.
6The company reported substantial cash, cash equivalents, and marketable securities of $5.81 billion as of December 31, 2004, indicating strong financial liquidity.
7Amgen noted potential negative impacts on product sales beginning in 2005 due to reimbursement changes resulting from the Medicare Modernization Act (MMA).

AMGEN INC Annual Report, Year Ended Dec 31, 2004

Summary

Key Highlights

Frequently Asked Questions